Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

49.85 +3.73 (+8.09%)

Streaming Delayed Price Updated: 10:53 AM EDT, Aug 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,647,168
Open	47.55
Bid (Size)	49.79 (100)
Ask (Size)	49.90 (100)
Prev. Close	46.12
Today's Range	47.23 - 50.02
52wk Range	40.77 - 104.32
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

August 04, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus AI Q2 Earnings Call Highlights ↗

July 31, 2026

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial...

Via MarketBeat

Performance

YTD	-20.1%	-20.1%
1 Month	-17.0%	-17.0%
3 Month	+0.8%	+0.8%
6 Month	-4.9%	-4.9%
1 Year	-10.2%	-10.2%

More News

Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset? ↗

July 31, 2026

Via Benzinga

Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares? ↗

July 31, 2026

Via The Motley Fool

Tempus AI (NASDAQ:TEM) Delivers Mixed Q2 Results with EPS Beat, Stock Slips in After-Hours Trading ↗

July 30, 2026

Via Chartmill

Tempus Reports Second Quarter 2026 Results

July 30, 2026

From Tempus AI, Inc.

Via Business Wire

3 Powerful AI Stocks Poised for the Next Massive Shift ↗

July 28, 2026

Via The Motley Fool

Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine

July 22, 2026

From Tempus AI, Inc

Via Business Wire

Tempus AI Bets on MRD Testing Growth With Personalis Acquisition ↗

July 20, 2026

Via MarketBeat

Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service

July 16, 2026

From Tempus

Via Business Wire

Tempus to Report Second Quarter 2026 Financial Results on July 30

July 09, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

June 25, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

June 11, 2026

From Tempus AI, Inc.

Via Business Wire

Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

June 09, 2026

From Ambry Genetics

Via Business Wire

Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner ↗

June 08, 2026

Via The Motley Fool

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

June 05, 2026

From Tempus AI, Inc.

Via Business Wire

Why Tempus AI Stock Is Surging On Thursday? ↗

June 04, 2026

Via Benzinga

Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

June 03, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

June 01, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

May 31, 2026

From Tempus AI, Inc.

Via Business Wire

What to Know About This Fund's $32.6 Million Porch Group Purchase ↗

May 30, 2026

Via The Motley Fool

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

May 30, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

May 29, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

May 29, 2026

From Tempus AI, Inc.

Via Business Wire

Frequently Asked Questions

Is Tempus AI, Inc. - Class A Common Stock publicly traded?

Yes, Tempus AI, Inc. - Class A Common Stock is publicly traded.

What exchange does Tempus AI, Inc. - Class A Common Stock trade on?

Tempus AI, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Tempus AI, Inc. - Class A Common Stock?

The ticker symbol for Tempus AI, Inc. - Class A Common Stock is TEM on the Nasdaq Stock Market

What is the current price of Tempus AI, Inc. - Class A Common Stock?

The current price of Tempus AI, Inc. - Class A Common Stock is 49.85

When was Tempus AI, Inc. - Class A Common Stock last traded?

The last trade of Tempus AI, Inc. - Class A Common Stock was at 08/07/26 10:53 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.